Baseimmune
Latest round
- Series A
Last raised
- Jan 2024
Total raised
- $16M
Investors
- 8
About Baseimmune
Based in London, UK, and founded in 2019 by CEO Joshua Blight, CSO Ariane C.a. Baseimmune, operates as a biotechnology company that leverages a proprietary AI-platform to design vaccines capable of withstanding pathogen mutations. In January 2024, Baseimmune Ltd.vc.67 million post-money. Baseimmune's discovery platform integrates genomic, proteomic, epidemiological, and immunological data to generate multi-target antigens and validate vaccine candidates. The company’s early-stage pipeline includes vaccines for malaria, coronaviruses, and African swine fever, employing advanced mRNA/LNP and viral vector technologies.
Who invested in Baseimmune
8 investors across 2 rounds
See all investors in Baseimmune
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Baseimmune
Who invested in Baseimmune?
Baseimmune has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Baseimmune raised?
Baseimmune has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Baseimmune last raise money?
Baseimmune's most recent round on record is a Series A, in Jan 2024.
What does Baseimmune do?
Based in London, UK, and founded in 2019 by CEO Joshua Blight, CSO Ariane C.
Where is Baseimmune headquartered?
Baseimmune is headquartered in London, UK.
Which VCs invest in companies like Baseimmune?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Baseimmune's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Baseimmune? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.